HHCP
HAE icon

Hilton Head Capital Partners’s Haemonetics HAE Stock Holding History

Hilton Head Capital Partners’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.83K Hold
51
– – ﹤0.01% 706
2026
Q1 		$2.87K Sell
51
-68
-57% -$4.43K ﹤0.01% 754
2025
Q4 		$9.54K Buy
+119
New +$8K 0.01% 566

Other funds holding HAE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Hilton Head Capital Partners's HAE Position: Q2 2026 in Review

Hilton Head Capital Partners held its Haemonetics (HAE) position steady in Q2 2026 at 51 shares worth $3.83K. The position accounts for ﹤0.01% of the portfolio, ranked #706.

Hilton Head Capital Partners first reported a position in HAE in Q4 2025 and has held it in 3 quarters since. The position peaked at $9.54K in Q4 2025. 329 funds tracked by Wall St. Rank hold HAE as of Q2 2026.

  • Hilton Head Capital Partners held 51 shares of Haemonetics worth $3.83K as of Q2 2026.
  • Hilton Head Capital Partners left its Haemonetics share count unchanged in Q2 2026.
  • Haemonetics made up ﹤0.01% of Hilton Head Capital Partners's portfolio in Q2 2026, its #706 holding.
  • Hilton Head Capital Partners first reported a position in Haemonetics in Q4 2025 and has held it in 3 quarters since.
  • Hilton Head Capital Partners's Haemonetics position peaked at $9.54K in Q4 2025.
  • 329 funds tracked by Wall St. Rank held Haemonetics as of Q2 2026.

Based on Hilton Head Capital Partners's 13F filing for Q2 2026, filed 27 Jul 2026.